F
Francesco Passamonti
Researcher at University of Insubria
Publications - 435
Citations - 28658
Francesco Passamonti is an academic researcher from University of Insubria. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 73, co-authored 371 publications receiving 23712 citations. Previous affiliations of Francesco Passamonti include Ospedale di Circolo e Fondazione Macchi & University Hospital of Basel.
Papers
More filters
Journal ArticleDOI
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Robert Kralovics,Francesco Passamonti,Andreas Buser,Soon Siong Teo,Ralph Tiedt,Jakob Passweg,André Tichelli,Mario Cazzola,Radek C. Skoda +8 more
TL;DR: Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages and a high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Journal ArticleDOI
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat,Domenica Caramazza,Rakhee Vaidya,Geeta George,Kebede H. Begna,Susan M. Schwager,Daniel L. Van Dyke,Curtis A. Hanson,Wenting Wu,Animesh Pardanani,Francisco Cervantes,Francesco Passamonti,Ayalew Tefferi +12 more
TL;DR: DPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF and predicts inferior leukemia-free survival.
Journal ArticleDOI
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
Luca Malcovati,Matteo G. Della Porta,Cristiana Pascutto,Rosangela Invernizzi,Marina Boni,Erica Travaglino,Francesco Passamonti,Luca Arcaini,Margherita Maffioli,Paolo Bernasconi,Mario Lazzarino,Mario Cazzola +11 more
TL;DR: Data show that the WHO classification of MDSs has a relevant prognostic value, and this classification, along with cytogenetics, might be useful in decisions regarding transplantation.
Journal ArticleDOI
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti,Francisco Cervantes,Alessandro M. Vannucchi,Enrica Morra,Elisa Rumi,Arturo Pereira,Paola Guglielmelli,Ester Pungolino,Marianna Caramella,Margherita Maffioli,Cristiana Pascutto,Mario Lazzarino,Mario Cazzola,Ayalew Tefferi +13 more
TL;DR: The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.